Regulatory
-
6 Tips To Ensure Your NDA/BLA Is Ready For FDA Review
2/25/2022
When preparing a marketing authorization application for an NDA or a BLA, one aspect that is easily overlooked by small start-ups and mature multi-product drug sponsors alike is verification that all commitments made to the FDA have been completed and that evidence of this has been submitted to the agency.
-
FDA Issues Proposal To Amend The Medical Device Quality System Regulation
2/24/2022
The FDA is proposing to amend the current good manufacturing practice (cGMP) requirements of 21 CFR Part 820: Quality System Regulation (QSR) to align more closely with the requirements of the internationally recognized ISO 13485:2016. The proposed amendment will also affect 21 CFR Part 4: Regulation of Combination Products.
-
FDA: Postapproval CMC Changes To Be Documented In Annual Reports
2/18/2022
New CDER guidance represents the FDA's thinking regarding the changes that BLA holders for specified biological products must document in an annual report. The products include therapeutic DNA plasmid products, therapeutic synthetic peptide products of 40 or fewer amino acids, mAb products for in vivo use, and therapeutic recombinant DNA-derived products.
-
Pharmaceutical Quality Compliance In 2022: Data Is Paramount
2/11/2022
Pharma quality and compliance leaders must anticipate potential manufacturing issues before they happen by leveraging risk-based methodologies, continuously monitoring their systems, and tracking the profusion of data generated during the process. This article outlines the potential of data and analytics to improve quality performance.
-
Clinical Trials: FDA Proposes Benefit-Risk Assessment For New Biologics
2/11/2022
The FDA's draft guidance illustrates how a drug’s benefits, risks, and risk management options factor into certain premarket and postmarket regulatory decisions. Communication between the sponsor and the FDA regarding the benefit-risk assessment is typically conducted at the end of the Phase 2 study, which can help influence the design of Phase 3 studies.
-
Variables Impacting Cell And Gene Therapy Development Success
2/3/2022
Explore four key interconnected variables exerting pressure on therapeutics developers to improve their processes earlier in the product’s development.
-
Case Study: Medical Writing — NDA Submission
2/2/2022
A sponsor’s medical writing lead leaves just months before NDA submission. This case study answers the question: Can a partner be found to complete medical writing midstream and then seamlessly transition everything back to the sponsor once a new lead is hired?
-
Put Quality Ahead Of Cost In Adverse Event Reporting Automation
2/1/2022
Quality has overtaken cost as a priority in plans for automating adverse event reporting. John Price analyses new research and outlines the progress of the sector toward end-to-end PV automation and explores the barriers that still remain.
-
Scott Gottlieb: The Future Of The CGT Regulatory Paradigm
2/1/2022
Though Dr. Gottlieb has become one of the most trusted voices through the COVID pandemic, I wanted to hear how his thoughts on the advanced therapies development paradigm have evolved in the past few years, and how he sees the world of CGT CMC changing in the future.
-
FDA Releases Draft Guidance On Use Of Real-World Evidence For Drug & Biological Products
1/19/2022
The FDA has issued new draft guidance in its latest effort to clarify its expectations regarding the integration of real-world data (RWD) and real-world evidence (RWE) into clinical research, product approvals, and post-approval monitoring of drugs. You can submit public comments until March 3, 2022.